专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1995001802A1 GROWTH DIFFERENTIATION FACTOR-7 审中-公开
标题翻译：生长差异因子-7
公开(公告)号：WO1995001802A1
公开(公告)日：1995-01-19
申请号：PCT/US1994007799
申请日：1994-07-08
申请人： THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE , LEE, Se-Jin , HUYNH, Thanh
发明人： THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
IPC分类号： A61K37/36
CPC分类号： C07K14/475 , A61K38/00 , C07K14/51
摘要： Growth differentiation factor-7 (GDF-7) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-7 polypeptide and polynucleotide sequences.
摘要翻译：公开了生长分化因子-7（GDF-7）及其多核苷酸序列和氨基酸序列。还公开了使用GDF-7多肽和多核苷酸序列的诊断和治疗方法。

2. 发明申请

WO1995000167A1 USE OF HUMAN GROWTH HORMONE FOR PREOPERATIVE ADMINISTRATION 审中-公开
标题翻译：人类生长激素用于预防性行政管理的使用
公开(公告)号：WO1995000167A1
公开(公告)日：1995-01-05
申请号：PCT/SE1994000596
申请日：1994-06-16
申请人： PHARMACIA AB , GLUCKMAN, Peter
发明人： PHARMACIA AB
IPC分类号： A61K37/36
CPC分类号： A61K38/27
摘要： The invention relates to the use of growth hormone (GH) or effective analogues thereof for the manufacture of a medicament intended for preoperative administration in order to reduce protein loss, especially for the manufacture of a medicament for the preparation of a patient for surgery or other elective situation where catabolism may be induced.
摘要翻译：本发明涉及生长激素（GH）或其有效类似物在制备用于术前给药的药物中的用途，以减少蛋白质损失，特别是用于制备用于制备用于手术或其它的患者的药物可能引起分解代谢的选择性情况。

3. 发明申请

WO1994022469A1 ENHANCEMENT OF LEARNING AND/OR MEMORY BY A HUMAN SOMATOTROPIN 审中-公开
标题翻译：人类SOMATOTROPIN的学习和/或记忆的增强
公开(公告)号：WO1994022469A1
公开(公告)日：1994-10-13
申请号：PCT/US1994003005
申请日：1994-03-22
申请人： OHIO UNIVERSITY
发明人： OHIO UNIVERSITY , PORTANOVA, Ronald, B. , PATTERSON, Michael, M. , WAGNER, Thomas, E.
IPC分类号： A61K37/36
CPC分类号： A61K38/27
摘要： The ability of an individual to learn and remember is improved by administering somatotropin to the individual before the task or information is first taught or presented to the individual. The present invention is the use of somatotropin (growth hormone) and related compounds for enhancing the mental abilities of normal, defective and deficient individual. Somatotropin is particularly useful for people with brain injury, mental retardation, and degenerative diseases such as Alzheimer's disease.
摘要翻译：通过在任务或信息首先被教导或呈现给个体之前，向个体施用生长激素来改善个体学习和记忆的能力。本发明是使用生长激素（生长激素）和相关化合物来增强正常，缺陷和缺乏个体的精神能力。生长激素对脑损伤，精神发育迟滞和退行性疾病如阿尔茨海默氏病尤其有用。

4. 发明申请

WO1994009812A1 METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-'beta' COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE 审中-公开
标题翻译：用于生产大量转化生长因子-β复合物和大量相关肽的方法
公开(公告)号：WO1994009812A1
公开(公告)日：1994-05-11
申请号：PCT/US1993010230
申请日：1993-10-25
申请人： KIRIN BREWERY COMPANY, LIMITED , LUDWIG INSTITUTE FOR CANCER RESEARCH , HELDIN, Carl-Henrik , MIYAZONO, Kohei , COLOSETTI, Pascal , HELMANN, Ulf , ISHII, Yasuyuki , OHASHI, Hideya
发明人： KIRIN BREWERY COMPANY, LIMITED , LUDWIG INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K37/36
CPC分类号： C07K14/47 , A61K38/00 , C07K14/495
摘要： This invention generally provides for a method of producing recombinant large latent TGF- beta by introducing nucleic acid sequences coding for LTBP and pro-TGF- beta into eukaryotic cells. This invention further provides for a method for producing recombinant LL-TGF- beta by introducing a DNA sequence for LTBP to an eukaryotic cell which expresses pro-TGF- beta . The invention also provides for the construction of a pME-TGF- beta 2 plasmid and its co-transfection with pRSVneo plasmid into BP-1-1 CHO cells which contains an amplified LTPBP cDNA sequence in the genome. The invention also provides for a method for treating the LL-TGF- beta 1 complex produced to bind to Ca2 ions during the purification process activity. An antibody to the large latent TGF- beta 1 complex is also disclosed herein. Additionally isolated L-LAP and a method to produce the same is provided herein.
摘要翻译：本发明通常提供通过将编码LTBP和前TGF-β的核酸序列引入真核细胞来生产重组大型潜在TGF-β的方法。本发明进一步提供了通过将LTBP的DNA序列引入表达前TGF-β的真核细胞来产生重组LL-TGF-β的方法。本发明还提供pME-TGF-β2质粒的构建及其与pRSVneo质粒的共转染到在基因组中含有扩增的LTPBP cDNA序列的BP-1-1CHC细胞中。本发明还提供了一种治疗在纯化过程活性期间产生以结合Ca 2+离子的LL-TGF-β1复合物的方法。本文还公开了对大潜伏性TGF-β1复合物的抗体。本文提供了另外分离的L-LAP及其制备方法。

5. 发明申请

WO1993024141A1 DELIVERY OF A CYTOTOXIC COMPOUND TO A CANCER CELL USING A PATHWAY OF PLASMINOGEN ACTIVATOR MATERIAL 审中-公开
标题翻译：将细胞毒素化合物递送至使用PLASMINOGEN ACTIVATOR材料途径的癌细胞
公开(公告)号：WO1993024141A1
公开(公告)日：1993-12-09
申请号：PCT/US1993005034
申请日：1993-05-27
申请人： THE UNIVERSITY OF TOLEDO
发明人： THE UNIVERSITY OF TOLEDO , JANKUN, Jerzy , HART, Richard
IPC分类号： A61K37/36
CPC分类号： C07K14/81 , A61K47/62
摘要： A method of delivering a cytotoxic compound to a cancer cell and getting the compound inside the cancer cell using a plasminogen material such as a plasminogen activator inhibitor (PAI-1). The toxic compound is coupled to PAI-1 to form a reaction product that is coupled with urokinase plasminogen activator (uPA) that is bound to the cell surface by uPA receptors (uPAR). The resultant complex is internalized to enter the cancer cell to deliver the cytotxic compound within the cell.
摘要翻译：使用纤溶酶原物质如纤溶酶原激活物抑制剂（PAI-1）将细胞毒性化合物递送至癌细胞并使化合物进入癌细胞内的方法。有毒化合物与PAI-1偶联以形成与uPA受体（uPAR）结合于细胞表面的尿激酶纤溶酶原激活物（uPA）结合的反应产物。所得的复合物被内化以进入癌细胞以将细胞毒化合物递送到细胞内。

6. 发明申请

WO1992020371A1 TARGETED DELIVERY OF BONE GROWTH FACTORS 审中-公开
标题翻译：有针对性地提供骨生长因子
公开(公告)号：WO1992020371A1
公开(公告)日：1992-11-26
申请号：PCT/US1992003840
申请日：1992-05-07
申请人： CELTRIX PHARMACEUTICALS, INC.
发明人： CELTRIX PHARMACEUTICALS, INC. , BENTZ, Hanne , ROSEN, David
IPC分类号： A61K37/36
CPC分类号： A61K38/1841 , A61K47/548 , A61K47/552 , A61K47/60 , A61K47/645
摘要： Methods and compositions for using conjugates of bone growth factors and targeting molecules in bone repair and augmentation are provided. The bone growth factor and targeting molecule are chemically conjugated to a crosslinker. The crosslinker is preferably a synthetic hydrophilic polymer. The bone growth factor is preferably TGF-β, activin, or bone morphogenic protein (BMP). Targeting molecules preferably have an affinity for bone, such as tetracycline, calcein, bisphosphonate, polyaspartic acid, polyglutamic acid, aminophosphosugars, or estrogen.

7. 发明申请

WO9208985A3 LIGAND-MEDIATED IMMUNOFUNCTIONAL HORMONE BINDING PROTEIN ASSAY METHOD 审中-公开
标题翻译：配体介导的免疫功能性蛋白质结合蛋白测定方法
公开(公告)号：WO9208985A3
公开(公告)日：1992-10-29
申请号：PCT/US9108664
申请日：1991-11-19
申请人： GENENTECH INC
发明人： CARLSSON LENA MARIANA SUSANN , CLARK ROSS GRAHAM , WONG WAI LEE TAN
IPC分类号： C12N15/02 , A61K31/00 , A61K38/00 , A61K38/27 , A61P15/00 , A61P19/00 , A61P19/02 , A61P19/08 , A61P43/00 , C07K14/72 , C07K16/26 , C07K16/28 , C12N5/10 , C12P21/08 , C12Q1/26 , C12Q1/28 , C12Q1/34 , C12Q1/40 , C12Q1/42 , G01N33/53 , G01N33/74 , A61K37/36
CPC分类号： C07K16/26 , A61K38/00 , C07K14/72 , C07K16/2869 , G01N33/74 , G01N2333/61 , G01N2333/65 , Y10S435/975
摘要： A ligand-mediated immunofunctional assay (LIFA) method for detecting the presence and the concentration of polypeptide hormone binding proteins which comprises capturing the binding protein with a solid phase bound first antibody, saturating the bound hormone binding protein with the ligand polypeptide hormone, and detecting the bound ligand polypeptide hormone with a detectably labeled second antibody specific for the ligand polypeptide hormone. In the absence of added saturating polypeptide hormone, the LIFA measures the amount of hormone binding protein bound to the endogenous ligand polypeptide hormone. A growth hormone binding protein assay illustrates the method of the present invention. LIFA assay results indicate that increased binding protein substantially increases growth hormone activity. Methods of use and formulations of growth hormone binding protein, growth hormone, insulin-like growth factor-I and insulin-like growth factor binding protein are disclosed.

8. 发明申请

WO1992009304A1 TREATMENT FOR OSTEOPOROSIS USING GROWTH HORMONE RELEASE FACTOR (GRF) IN COMBINATION WITH PARATHYROID HORMONE (PTH) 审中-公开
标题翻译：使用生长激素释放因子（GRF）与PARATHYROID HORMONE（PTH）联合治疗骨质疏松症
公开(公告)号：WO1992009304A1
公开(公告)日：1992-06-11
申请号：PCT/US1991008106
申请日：1991-11-01
申请人： RECKER, Robert, R.
IPC分类号： A61K37/36
CPC分类号： A61K38/29 , A61K38/25 , A61K2300/00
摘要： A method of treating osteoporosis, especially post-menopausal osteoporosis, by administering on a periodic but regular basis to a patient growth hormone releasing factor, GRF(1-44)-NH2, or a biologically active analog thereof, and concurrently administering parathyroid hormone, PTH(1-34)-NH2 and continuing the administration until bone mass increases and the patient's calcium balance becomes positive and indicates a mineral accumulation in the skeleton.

9. 发明申请

WO1992002246A1 GROWTH FACTOR COMPOSITIONS, PREPARATION AND USE 审中-公开
标题翻译：生长因子组成，制备和使用
公开(公告)号：WO1992002246A1
公开(公告)日：1992-02-20
申请号：PCT/US1991005396
申请日：1991-07-30
申请人： PARIKH, Indu
发明人： NARDI, Ronald , AMARANT, Tanchum , GUGLIETTA, Antonio
IPC分类号： A61K37/36
CPC分类号： C07K14/485 , A61K38/00
摘要： The invention in growth factor compositions includes: a novel compound which is a separate pure nicked or pure non-nicked species of epidermal growth factor EGF1-48 or its hEGF1-47 or hEGF1-49 congener compound, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition in dosage form comprising an effective amount of the novel compound; and use thereof for treating abnormal cell growth conditions including gastrointestinal/duodenal lesions; and methods of making the pure hEGF species. This unique therapeutic utility is enhanced by the unexpected and heretofore unappreciated structural stability and resistance of the pure species to enzymatic degradation.
摘要翻译：本发明在生长因子组合物中包括：一种新型化合物，其为分离的纯切口或纯非切口的表皮生长因子EGF1-48或其hEGF1-47或hEGF1-49同源化合物或其药学上可接受的盐; 包含有效量的新化合物的剂型的药物组合物; 及其用于治疗包括胃肠/十二指肠损伤的异常细胞生长条件的用途; 以及制备纯hEGF物种的方法。这种独特的治疗效用通过意想不到的和迄今为止尚未被欣赏的结构稳定性和纯物质对酶降解的抗性而增强。

10. 发明申请

WO1990011084A1 ENDOTHELIAL CELL GROWTH FACTOR, ISOLATION AND EXPRESSION 审中-公开
标题翻译：内皮细胞生长因子，分离和表达
公开(公告)号：WO1990011084A1
公开(公告)日：1990-10-04
申请号：PCT/US1990001568
申请日：1990-03-22
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , FERRARA, Napoleone , GOSPODAROWICZ, Denis , PLOUET, Jean
IPC分类号： A61K37/36
CPC分类号： C07K14/52 , A61K38/00
摘要： A novel growth factor specific for vascular endothelial cells has been identified in conditioned medium of bovine pituitarly derived folliculo stellate cells. This factor, named folliculo stellate derived growth factor (FSdGF) or vascular endothelial growth factor (VEGF), was purified to homogeneity by a combination of exclusion chromatography. Mono S ion exchange chromatography and hydrophobic chromatography on a C4 reverse phase HPLC column. The factor is also found in the murine AtT-20 cell line. FSdGF, having a molecular weight of about 43,000 daltons, was characterized as a glycoprotein composed of two homologous subunits with a molecular weight of about 23,000 daltons.
摘要翻译：已经在牛垂体衍生的卵泡星状细胞的条件培养基中鉴定了血管内皮细胞特异性的新型生长因子。称为卵泡星状衍生生长因子（FSdGF）或血管内皮生长因子（VEGF）的因子通过排除色谱法的组合纯化至均质。在C4反相HPLC柱上进行Mono S离子交换层析和疏水层析。该因子也在鼠AtT-20细胞系中发现。具有约43,000道尔顿分子量的FSdGF被表征为由分子量约23,000道尔顿的两个同源亚基组成的糖蛋白。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式